Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ilaria, Dragoni"'
Autor:
Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, the CDD SPIKE-1 Project Team
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives The primary objective is to evaluate the efficacy of camostat to prevent respiratory deterioration in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Secondary objectives include assessment of
Externí odkaz:
https://doaj.org/article/e31a8454fa154c06ae0d8991f49959f8
Autor:
Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, and the CDD SPIKE-1 Project Team
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/b21f19e815dd45c1a5e94555ef323a1a
Autor:
Sarah Halford, Gareth J. Veal, Stephen R. Wedge, Geoffrey S. Payne, Chris M. Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M. Salisbury, Maxime Chénard-Poirier, Alastair Greystoke, Elizabeth C. Howell, William A. Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C. Keun, Udai Banerji, Ruth Plummer
Publikováno v:
Clin Cancer Res
Purpose: Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-clas
Autor:
Ruth Plummer, Udai Banerji, Hector C. Keun, George Petrides, Mihaela Rata, Chris Plummer, Karen Morris, William A. Innes, Elizabeth C. Howell, Alastair Greystoke, Maxime Chénard-Poirier, Becky M. Salisbury, Sarah Potter, Kathrin Heinzmann, Ilaria Dragoni, Philip Sloan, Chris M. Bacon, Geoffrey S. Payne, Stephen R. Wedge, Gareth J. Veal, Sarah Halford
Purpose:Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-class
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9da6bf5d5915d482989d62e386cae2f
https://doi.org/10.1158/1078-0432.c.6533131.v2
https://doi.org/10.1158/1078-0432.c.6533131.v2
Autor:
Ruth Plummer, Udai Banerji, Hector C. Keun, George Petrides, Mihaela Rata, Chris Plummer, Karen Morris, William A. Innes, Elizabeth C. Howell, Alastair Greystoke, Maxime Chénard-Poirier, Becky M. Salisbury, Sarah Potter, Kathrin Heinzmann, Ilaria Dragoni, Philip Sloan, Chris M. Bacon, Geoffrey S. Payne, Stephen R. Wedge, Gareth J. Veal, Sarah Halford
supplementary data: Methods, tables, figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af17ae9e71a78dc3c42f946b96696d2
https://doi.org/10.1158/1078-0432.22490317
https://doi.org/10.1158/1078-0432.22490317
Autor:
Richard A. Noble, Huw Thomas, Yan Zhao, Lili Herendi, Rachel Howarth, Ilaria Dragoni, Hector C. Keun, Christopher P. Vellano, Joseph R. Marszalek, Stephen R. Wedge
Background We evaluated the therapeutic potential of combining the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 with the mitochondrial respiratory Complex I inhibitor IACS-010759, for the treatment of diffuse large B-cell lymphoma (DLBCL),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd17a33d17f0ddd287dcda7549f62ff
http://hdl.handle.net/10044/1/97953
http://hdl.handle.net/10044/1/97953
Autor:
Richard A, Noble, Huw, Thomas, Yan, Zhao, Lili, Herendi, Rachel, Howarth, Ilaria, Dragoni, Hector C, Keun, Christopher P, Vellano, Joseph R, Marszalek, Stephen R, Wedge
Publikováno v:
British journal of cancer. 127(5)
We evaluated the therapeutic potential of combining the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 with the mitochondrial respiratory Complex I inhibitor IACS-010759, for the treatment of diffuse large B-cell lymphoma (DLBCL), a potential
Autor:
Kathrin Heinzmann, Gareth J. Veal, Laura Brotherton, William Townsend, Martin J. S. Dyer, Chris M. Bacon, Ilaria Dragoni, Pamela McKay, Elizabeth Ruth Plummer, Hector C. Keun, Harriet S. Walter, Kim Linton, Steve R. Wedge, Sarah Halford, Alexandros P. Siskos
Publikováno v:
Halford, S E R, Walter, H, McKay, P, Townsend, W, Linton, K, Heinzmann, K, Dragoni, I, Brotherton, L, Veal, G, Siskos, A, Keun, H C, Bacon, C, Wedge, S, Dyer, M J S & Plummer, E R 2021, ' Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ', Journal of Clinical Oncology, vol. 39, no. 15_suppl, pp. 3115-3115 . https://doi.org/10.1200/jco.2021.39.15_suppl.3115
ASCO Annual Meeting I
ASCO Annual Meeting I
3115 Background: Tumours rely on lactate transporters (MCT1-4) to maintain glycolytic flux and avoid intracellular acidification. In haematological tumours the MCT1 transporter acts as a lactate and pyruvate exporter. AZD3965 is a potent and specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90d8d48f356d0ee9e4a7761b45a9d92
https://doi.org/10.1200/jco.2021.39.15_suppl.3115
https://doi.org/10.1200/jco.2021.39.15_suppl.3115
Autor:
Lorenzo Biassoni, Julie Silvester, Jack Barton, Claire Barton, Muhammad Al-Hajj, Clare Marriott, Talia Gileadi, Thalia Loka, John Anderson, Simon Thomas, Karin Straathof, Stephanie Traub, Sarah Inglott, Lesley Robson, Evangelia Kokalaki, Giuseppe Barone, Kieran McHugh, Lily Elson, Karen Dyer, Karen Howe, Sarita Depani, Teresa Marafioti, Ami Bedi, Natalie Sizer, Sian Stafford, Nigel Westwood, Olumide Ogunbiyi, Gordon Weng-Kit Cheung, Barry Flutter, Sue Brook, Martin Pule, Dyanne Rampling, Gary Wright, Kimberly Gilmour, Rebecca Wallace, Catriona Duncan, David P. Edwards, Ailish Barry, William Day, Neha Jain, Ilaria Dragoni, Ayse U. Akarca
Publikováno v:
Science Translational Medicine. 12
The reprogramming of a patient’s immune system through genetic modification of the T cell compartment with chimeric antigen receptors (CARs) has led to durable remissions in chemotherapy-refractory B cell cancers. Targeting of solid cancers by CAR-
Autor:
Roisin NicAmhlaoibh, Robert Clarke, Bruno M Simões, Julia Margaret Wendy Gee, Ilaria Dragoni, Verity Sabin, Andrew H. Sims, Sacha J Howell, Angélica Santiago-Gómez, Elisabeth Trivier
Despite the effectiveness of endocrine therapies to treat estrogen receptor-positive (ER+) breast tumours, two thirds of patients will eventually relapse due tode novoor acquired resistance to these agents. Cancer Stem-like Cells (CSCs), a rare cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534e837c2b0603b87290ebe8850f70da
https://doi.org/10.1101/558528
https://doi.org/10.1101/558528